Actively Recruiting
Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Led by Peking University Third Hospital · Updated on 2023-12-27
120
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
SBRT (stereotactic radiotherapy) can provide a higher dose to the target area without increasing the risk of surrounding normal tissue / organ injury in selective cases. At present, SBRT has been widely used in radiotherapy of lung cancer and it can also play a better local control for lung metastasis. However, there are parallel organs and series organs in the chest, and different organs have different tolerance to radiotherapy, so the toxicities of SBRT in different sites are different, and the prescription dose is also different. This study intends to make a detailed division of the chest region and explore the safety and efficacy of SBRT in different areas. It is divided into four types: chest wall type: the lesion is directly adjacent or overlapped with the chest wall; peripheral type: the lesion is more than 1cm away from the chest wall and more than 2cm away from the bronchial tree; central type: the lesion is less than 2cm away from the bronchial tree; ultral-central type: the lesion is directly adjacent or overlapped with the mediastinal structure. 48-60Gy / 4-10f (EQD2 = 62.5Gy \~ 99.7Gy) was given according to the location of the tumor. Main outcome measures are local progression free survival and radiation toxicities; secondary outcome measure is overall survival.
CONDITIONS
Official Title
Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathological diagnosis of a malignant tumor
- Target lesion located in one of five specific chest types with diameter 64 5 cm
- No extensive systemic metastasis or controlled metastasis after prior treatment
- Karnofsky Performance Score (KPS) greater than 70
- No serious or uncontrolled underlying diseases such as severe hypertension, diabetes, cardiovascular or cerebrovascular diseases, or organ dysfunction
- Patient expected to tolerate radiotherapy
You will not qualify if you...
- Poor pulmonary function or symptoms preventing lying flat or cooperating with treatment
- Poor general condition with expected survival less than 3 months
- Psychiatric conditions or poor compliance preventing completion of treatment
- Any other reason deemed by the researcher that makes participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191
Actively Recruiting
Research Team
Z
Zhe Ji, M.D.
CONTACT
J
Junjie Wang, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here